Facilities & Capacity

Bio-Techne confirms $50m reagents plant to support CGTs

Bio-Techne will build a 50,000 square-foot plant in Minnesota with an initial capacity of $140 million of E. coli-derived recombinant proteins to support cell and gene therapy developers. After months of talk, life sciences services and consumables firm Bio-Techne has laid concrete plans to build a facility in St Paul, Minnesota to produce GMP reagent proteins for use in cell and gene therapy applications. “The facility is expected to go through qualifications in approximately one year, with commercial sales expected…

Gene therapy demand drives Cytovance pDNA expansion

Cytovance Biologics has added plasmid DNA (pDNA) production capacity at its Oklahoma City facility citing growing demand from gene therapy developers. The single-use production system is capable of making both critical reagent grade – for research – and cGMP grade pDNA in quantities ranging from 1g to 50g. It can manufacture smaller quantities for R&D. Jesse McCool, Cytovance chief technology officer (CTO), framed the investment as part of the firm’s effort to position itself as a key gene therapy supply…

Biogen’s services revenues fall; Aducanumab re-emerges

Biogen saw its manufacturing services revenue slide in Q3 following the sale of its plant in Hillerod, Denmark. According to Biogen’s Q3 report the firm’s “other revenues” –those not generated by drug product sales – fell 26% year on year to $110m. CFO Jeff Capello attributed the decline to the divestiture of the firm’s biologics manufacturing in Hillerod facility to Fujifilm. “Total other revenues in the third quarter decreased 26% versus the prior year driven by the decline in our…

WuXi selects Irish site for first vaccine plant

Chinese CDMO WuXi Biologics has laid plans to build a manufacturing facility in County Louth, Ireland, months after forming a vaccine joint venture. In May, WuXi Biologics formed a joint venture with Shanghai-based Hile Bio-Technology to service a 20-year manufacturing contract with an undisclosed vaccine developer estimated to be worth more than $3 billion (€2.7 billion). At the time, the Chinese contract development and manufacturing organization (CDMO) said it was scouting for a dedicated vaccine manufacturing site, and it turns…

Genmab signs up to Lonza’s Ibex design and development service

Danish drugmaker Genmab has upped its relationship with long-term CDMO partner Lonza by reserving space at the Ibex Design and Ibex Develop facilities in Switzerland. Contract development and manufacturing organization (CDMO) is constructing a biopark at its site and headquarters in Visp, Switzerland, to support its range of Ibex biologics development and manufacturing services. Denmark’s Genmab has been working with Lonza on multiple antibody-based programs since 2002, and with its strategy to fully outsource its biomanufacturing, the firm has reserved…

Combigene teams with Cobra and NBR on epilepsy gene therapy

Cobra Biologics will produce the AAV viral vector for Combigene’s epilepsy gene therapy from its facilities in Keele, UK. Nordic gene therapy company Combigene’s CG01 candidate is based on an adeno-associated viral vector (AAV) which administers a combination of neuropeptide Y (NPY) and its receptor Y2 directly to the part of the brain where epileptic seizures begin. The project has received funding from the European Union’s Horizon 2020 research and innovation program and the manufacturing process was developed at the…

Avid expands Californian PD and lab capabilities

Process development (PD) is a vital CDMO function and one that Avid will continue to invest in, the firm says as it opens a multi-million-dollar expansion in Orange County. Avid Bioservices opened the doors on an expansion at its site in Orange County, California last week. The multi-million-dollar investment increases the contract development and manufacturing organization (CDMO) process development (PD) laboratory footprint four-fold, adding 24 benchtop process development bioreactors, ranging from 3 liter to 15-liter capacity in single-use and glass.…

Sanofi opens $320m continuous biologics plant in MA

French drugmaker Sanofi Genzyme has completed process qualification runs at a plant in Framingham based on digital and continuous biologics production technologies. Sanofi announced today that following successful process qualification runs in the last quarter, it has inaugurated a digitally-enabled, continuous manufacturing facility at its site in Framingham, Massachusetts. Nicolas Kressmann, a spokesperson from Sanofi, told Bioprocess Insider that the plant represented an investment of €290 million ($320 million) between 2014 and 2018. The French Big Biopharma firm spends around…

CDMO focus: Strategic gene therapy deals and $250m sell-off

Lonza strengthens gene therapy partnership with Prevail; Paragon and Brammer evolving form hyperstacks over to iCELLis units for Sarepta; Mallinckrodt sells off Biovectra. Welcome to Bioprocess Insider’s CDMO round-up. First up in this contract development and manufacturing organization (CDMO) round-up is Swiss firm Lonza, which is upping its partnership with Prevail Therapeutics. Lonza has worked on the process development of Prevail’s two lead gene therapy programs since 2018 and will now take the partnership to the next stage, using a…

J&J expands Irish footprint with €300m plant and 200 new jobs

J&J subsidiary Janssen has opened a 206,000 square-foot biologics manufacturing facility at its site in Ringaskiddy, county Cork. Janssen Science Ireland announced its plans to construct a €300 million biomanufacturing plant at its site in Ringaskiddy in 2017 and this week the 19,100 m2 (206,000 square feet) opened its doors. “Our manufacturing facilities in Cork are at the cutting-edge of delivering healthcare solutions, which is an important part of our credo commitment to provide the highest quality products to patients,”…